From INVESCO to APPLE: Insights into Clarus Wealth Advisors Q4 2022 vs. Q1 2023 13F Holdings
Ava Hoppe | 2 May, 2023
The quarterly 13F filings are out, and it’s time to assess the changes in the investment portfolio of Clarus Wealth Advisors. This report compares the Q4 2022 and Q1 2023 holdings of key stocks by this advisory firm in the United States. While this data does not cover every move made by Clarus, it still provides insight into the firm's investment strategy and objectives.
Let's dive in and analyze the changes in holdings of some of the biggest companies in Clarus' portfolio:
APPLE INC (AAPL)
AAPL remains among the top holdings of Clarus Wealth Advisors, even though shares declined by 11.5% from Q4 2022 to Q1 2023. The number of shares held decreased from 54,239 to 48,016, representing a notable sale of approximately 6,223 shares. While the percentage change might not appear to be significant, the monetary value of the reduction, from a $7,090,000 value in Q4 2022 to a $7,906,000 value in Q1 2023, is quite substantial.
BERKSHIRE HATHAWAY INC DEL (BRK-A and BRK-B)
Clarus did not hold any shares of BRK-A in Q4 2022. Meanwhile, the firm purchased 2,408 shares in Q1 2023, worth approximately $752,000. This suggests that Clarus believes in the company's potential and is considering its addition to their portfolio.
PACER FDS TR (COWZ, ALTL, and ECOW)
Clarus owns a diverse range of shares in the Pacer FDS Trust, including COWZ, ALTL, and ECOW. While there were fluctuations in ownership percentage, stock values, and number of shares, none of these changes were drastic. In fact, Clarus decreased ALTL shares by only 109, a reduction of 0.2%, despite their steep increase in value by 109.3%.
MICROSOFT CORP (MSFT)
A slight reduction in MSFT shares was seen in Clarus' portfolio, decreasing from 5,072 in Q4 2022 to 3,887 in Q1 2023. The decline reflects a -2.3% change in ownership and was likely due to the emergence of newer investment opportunities.
LOCKHEED MARTIN CORP (LMT)
Clarus experienced a 7.3% upswing in share ownership in LMT, with the number of shares held increasing from 3,288 to 3,326. Additionally, the value of those shares increased from $1,519,000 in Q4 2022 to $1,630,000 in Q1 2023.
TESLA INC (TSLA)
Although TSLA did not have any shares in Clarus' portfolio in Q4 2022, there were 3,406 in Q1 2023. Considering the high value of Tesla's shares, it reflects the advisory firm's focus on including high-growth opportunities in their portfolio.
Other Changes
Clarus has diversified their portfolio with several other holdings. FIRST TR EXCHANGE-TRADED FD, VANGUARD INDEX FDS, and SPDR SER TR saw fractional changes in the number of shares held by Clarus Wealth Advisors. These changes are indicative of the firm's ongoing efforts to diversify their holdings, balancing out high-risk bets with more conservative investments.
Conclusion
The 13F filings provide an insight into the US investment advisory firm’s investment strategy, which is based on the possibilities of high growth and risk, intermingled with conservative capital preservation endeavors. Although the holdings and investments of Clarus Wealth Advisors are not comprehensive, this comparison of the Q4 2022 and Q1 2023 report reflects the company's objectives and strategy in managing their clients' investments.
Other Posts
- Unlocking Growth: SLR Credit Solutions Empowers Ansira Partners Inc. with Senior Credit Facility
- Revealing Cambridge Investment Research Advisors' Q3 vs. Q4 2022 Fund Holdings
- Comparing Northstar Investment Advisors LLC's Q1 and Q2 2021 13F Holdings
- Investment Report: Strategic Investment Management, LLC Q3 2022 vs. Q4 2022
- The Engle Capital Management, L.P. Q3 2022 to Q4 2022 13F Holdings Analysis
- Unlocking the Future of Market Insights: mTab's Strategic Growth Journey
- Growing Your Wealth: Everence Capital Management's Quarterly Holdings Comparison
- Asset Planning Services, Ltd.: A Comprehensive Look at Q3 2021 vs. Q4 2021 13F Holdings
- The Rise and Fall: A Look into Edmp, Inc.'s Q4 2022 vs. Q1 2023 13F Holdings
- **Unlocking Potential: Navidea Biopharmaceuticals and CRG Settle Ongoing Litigation**